Stock Events

Biocure Technology 

€0
0
+€0+0% Thursday 06:02

Statistics

Day High
0
Day Low
0
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
960,835
P/E Ratio
0.03
Dividend Yield
-
Dividend
-

Earnings

30SepConfirmed
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-0.01
-0.01
-0
0
Expected EPS
N/A
Actual EPS
-0.0103

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1WH.F. It's not an investment recommendation.

About

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
Show more...
CEO
Dr. Björn Cochlovius Ph.D.
Country
CA
ISIN
CA09075T1075
WKN
000A2JGTL

Listings